Cure8 research brief
Reports effectiveness and safety of risankizumab specifically in East Asian participants from global phase 2b/3 UC trials, which may inform regional applicability of trial results for people with moderate-to-severe ulcerative colitis.
Adult patients with moderate-to-severe ulcerative colitis, clinicians, researchers, and people considering biologic/IL‑23 therapy
This is a post hoc analysis of patients enrolled in global phase 2b/3 trials, focusing on those from China, Japan, South Korea, and Taiwan. The induction study used intravenous risankizumab 1200 mg versus placebo for 12 weeks; responders entered a maintenance study with subcutaneous risankizumab 180 mg, 360 mg, or placebo every 8 weeks for 52 weeks.
The abstract reports higher remission rates and improvements on clinical, endoscopic, and histologic measures with risankizumab and no new safety signals in this East Asian subgroup.
The report summarizes trial data for a specific regional subgroup rather than presenting new randomized evidence limited to East Asia; subgroup (post hoc) analyses can be helpful for understanding consistency across populations but are generally less definitive than primary trial results.
Talk with your clinician if you are considering treatment options—this abstract does not replace individualized medical advice and does not provide full safety or prescribing information.
This is a post hoc subgroup analysis reported as an abstract from phase 2b/3 trials; subgroup findings are useful for consistency checks but less definitive than prespecified primary analyses. The abstract alone does not replace full trial reports or regulatory labeling.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.
IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for...
